SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has dispatched a letter to shareholders providing a web-link and QR code to access the Integrated Annual Report for FY 2025-26. The company has also announced the 38th Annual General Meeting (AGM) to be held on September 29, 2026, and proposed a dividend of Rs. 0.40 per equity share.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by SEBI regulations.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the notice of its 38th Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The company has also released its annual report for the financial year 2025-26, which includes details of the company's performance, governance, and future plans.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its Annual Report for the Financial Year 2025-26, along with the notice of its 38th Annual General Meeting (AGM) scheduled for September 29, 2026. The company has also provided details for the AGM, including record date for dividend, cut-off date for e-voting eligibility, and book closure dates.

SMS Pharmaceuticals Ltd

CARE Ratings Limited has reaffirmed the credit ratings of SMS Pharmaceuticals Ltd, assigning a 'CARE A' rating with a stable outlook for the company's long-term bank facilities and a 'CARE A1' rating for its short-term bank facilities.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has published a newspaper advertisement informing shareholders about the 38th Annual General Meeting to be held on September 29, 2026, through Video Conference or Other Audio Visual Means.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has changed the record date for dividend from 16th September, 2026 to 22nd September, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has changed the date of its 38th Annual General Meeting from 23rd September, 2026 to 29th September, 2026, due to unavoidable circumstances and administrative constraints.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the publication of a newspaper advertisement regarding its 38th Annual General Meeting to be held through Video Conference/Other Audio Visual Means on September 23, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced an intimation on tax deduction at source on dividend. The company has recommended a final dividend of Rs.0.40 per equity share for the financial year ended March 31, 2026, subject to approval by shareholders at the ensuing Annual General Meeting. The record date for determining entitlement to the final dividend is fixed as Wednesday, 16th September, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its audited standalone and consolidated financial results for the first quarter ended June 30, 2026, which are available on its website and in newspapers.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has released its Q1FY27 investor presentation, highlighting a 6% YoY revenue growth, sustained EBITDA margin of ~20%, and an 8% YoY PAT growth. The company has completed 4 DMF/CEP filings and is on track to meet its FY27 target of 10 filings. A ₹280 crore capex programme is progressing as planned, and the board has approved an infusion of up to ₹50 crore into its subsidiary SMS Peptides Private Limited.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd reported a 6% YoY growth in revenue for Q1FY27, driven by broad-based growth across high-value APIs, with gross margin remaining above 45% and EBITDA margin sustained at ~20%. The company completed 4 DMF/CEP filings and is on track to meet its FY27 target of 10 filings. A ₹280 crore capex programme is progressing as planned, and the company has approved an infusion of up to ₹50 crore into its subsidiary SMS Pepdes Private Limited.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd announced its Q1 FY2026 financial results, with a profit before tax of Rs. 2,814.42 lakhs. The company also approved the re-appointment of Mr. Ramesh Babu Potluri as Managing Director for a term of 5 years. Additionally, the board approved giving a loan to its subsidiary, SMS Peptides Private Limited, up to Rs. 50 crores.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the fixation of record date for its 38th Annual General Meeting (AGM) and the payment of dividend for the financial year 2025-26. The company has also approved the standalone and consolidated un-audited financial results for the first quarter ended 30th June, 2026. Additionally, the Board of Directors has re-appointed Mr. Ramesh Babu Potluri as the Chairman and Managing Director of the company for a term of 5 years.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd re-appoints Ramesh Babu Potluri as Managing Director for 5 years. The company also approved the standalone and consolidated un-audited Financial Results for the first quarter ended 30th June, 2026. Additionally, the Board approved the loan to be given to SMS Peptides Private Limited, a subsidiary company, up to an aggregate amount not exceeding Rs. 50 Crores.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its financial results for the quarter ended 30th June, 2026, with revenue from operations at Rs. 20,696.49 lakhs and a net profit of Rs. 2,814.42 lakhs. The company has also approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for a term of 5 years, subject to shareholder approval. Additionally, the company has approved giving a loan to its subsidiary, SMS Peptides Private Limited, up to Rs. 50 crores.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its Q1 FY26 financial results, with revenue from operations at Rs. 20,696.49 lakhs and profit before tax at Rs. 2,814.42 lakhs. The company has also approved the re-appointment of its Managing Director, Mr. Ramesh Babu Potluri, for a term of 5 years. Additionally, the company has approved giving a loan to its subsidiary, SMS Peptides Private Limited, up to Rs. 50 crores.

SMS Pharmaceuticals Ltd

The Board Meeting of SMS Pharmaceuticals Ltd has been rescheduled from 1st August 2026 to 31st July 2026 due to unavoidable administrative exigencies.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has scheduled a board meeting on August 1, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.